Cargando…

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study

The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12‐ and 18‐month rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokota, Kenji, Uchi, Hiroshi, Uhara, Hisashi, Yoshikawa, Shusuke, Takenouchi, Tatsuya, Inozume, Takashi, Ozawa, Kentaro, Ihn, Hironobu, Fujisawa, Yasuhiro, Qureshi, Anila, de Pril, Veerle, Otsuka, Yasushi, Weber, Jeffrey, Yamazaki, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916343/
https://www.ncbi.nlm.nih.gov/pubmed/31638282
http://dx.doi.org/10.1111/1346-8138.15103
Descripción
Sumario:The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12‐ and 18‐month recurrence‐free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19–2.24; P = 0.4390). No new safety signals were reported for Japanese patients. Results were consistent with those from the CheckMate 238 global population, indicating that nivolumab has the potential to be a treatment option for Japanese patients with resected melanoma who are at high risk of recurrence.